Charles L. Wiseman
- Oncology top 5%
- Molecular Biology
- Cancer Research top 5%
- Pathology and Forensic Medicine top 5%
- Modeling and Simulation top 1%
- Co-authors
- Kun LiaoAmi RadunskayaL. G. de PillisCary A. PresantDouglas W. BlayneyKirit GalaM. Ernest MarshallKaren M. Butler
- Topics
- Immunotherapy and Immune Responses (18 papers)Cancer Immunotherapy and Biomarkers (12 papers)Monoclonal and Polyclonal Antibodies Research (7 papers)
- Partner nations
- United StatesUnited KingdomSwitzerland
In The Last Decade
Charles L. Wiseman
51 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 121
- Oncology 680
- Molecular Biology 467
- Cancer Research 425
- Pathology and Forensic Medicine 424
- Modeling and Simulation 343
Countries citing papers authored by Charles L. Wiseman
This map shows the geographic impact of Charles L. Wiseman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles L. Wiseman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles L. Wiseman more than expected).
Fields of papers citing papers by Charles L. Wiseman
This network shows the impact of papers produced by Charles L. Wiseman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles L. Wiseman. The network helps show where Charles L. Wiseman may publish in the future.
Co-authorship network of co-authors of Charles L. Wiseman
This figure shows the co-authorship network connecting the top 25 collaborators of Charles L. Wiseman. A scholar is included among the top collaborators of Charles L. Wiseman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles L. Wiseman. Charles L. Wiseman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 0 | |
| 3 | 1 | |
| 4 | 19 | |
| 5 | 5 | |
| 6 | 11 | |
| 7 | 13 | |
| 8 | 21 | |
| 9 | 134 | |
| 10 | 2 | |
| 11 | 3 | |
| 12 | 58 | |
| 13 | 62 | |
| 14 | 47 | |
| 15 | 69 | |
| 16 | 87 | |
| 17 | Increased T-helper lymphocytes following active specific intralymphatic immunotherapy of cancer. | 2 |
| 18 | 28 | |
| 19 | 7 | |
| 20 | 358 |
About Charles L. Wiseman
Charles L. Wiseman is a scholar working on Oncology, Immunology and Cancer Research, having authored 53 papers that have together received 1.8k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (18 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Monoclonal and Polyclonal Antibodies Research (7 papers). The work is most often cited by research in Modeling and Simulation (343 citations), Cancer Research (425 citations) and Oncology (680 citations). Charles L. Wiseman has collaborated with scholars based in United States, United Kingdom and Switzerland. Frequent co-authors include Kun Liao, Ami Radunskaya, L. G. de Pillis, Cary A. Presant, Douglas W. Blayney, Kirit Gala, M. Ernest Marshall, Karen M. Butler, George R. Blumenschein and Aman U. Buzdar. Their work appears in journals such as The Lancet, Journal of Clinical Oncology and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.